Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

In this prospective, open-label, multicenter phase 1/2 dose escalation study, we used a next-generation, mono-pegylated interferon (IFN) α-2b isoform, ropeginterferon alfa-2b. The unique feature of ropeginterferon alfa-2b is a longer elimination half-life, which allows administration every 2 weeks....

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Gisslinger, Heinz, Zagrijtschuk, Oleh, Buxhofer-Ausch, Veronika, Thaler, Josef, Schloegl, Ernst, Gastl, Guenther A., Wolf, Dominik, Kralovics, Robert, Gisslinger, Bettina, Strecker, Karin, Egle, Alexander, Melchardt, Thomas, Burgstaller, Sonja, Willenbacher, Ella, Schalling, Martin, Them, Nicole C., Kadlecova, Pavla, Klade, Christoph, Greil, Richard
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2015
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4608390/
https://ncbi.nlm.nih.gov/pubmed/26261238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-04-637280
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg